Skip to main content

Advertisement

Table 2 Frequency of positivity of APLA in MS and controls

From: Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study

Target antigens Exacerbation Remission Controls
  IGG IGM IGG IGM IGG IGM
β2-GP-I 0/17 (0%) 14/17 (82%) 0/7 (0%) 2/7 (28%) 1/21 (4%) 0/21 (0%)
VIIa 0/17 (0%) 10/17 (59%) 0/17 (0%) 0/7 (0%) 0/21 (0%) 0/21 (0%)
CL 0/17 (0%) 14/17 (82%) 0/17 (0%) 2/7 (28%) 0/21 (0%) 0/21 (0%)
PC 0/17 (0%) 13/17 (76%) 0/17 (0%) 1/7 (14%) 0/21 (0%) 0/21 (0%)
PS 0/17 (0%) 12/17 (71%) 0/17 (0%) 1/7 (14%) 0/21 (0%) 0/21 (0%)
PE 0/17 (0%) 14/17 (82%) 0/17 (0%) 2/7 (28%) 0/21 (0%) 0/21 (0%)
At least one 0/17 (0%) 15/17 (88%) 0/17 (0%) 4/7 (57%) 1/21 (4%) 0/21 (0%)
  1. The abbreviations: β2-GP-I = β2-glycoprotein-I; VIIa: Factor VIIa; CL = cardiolipin; PC = phosphatidylcholine; PS= phosphatidylserine; PE = phosphatidylethanolamine